One developing strategy for obesity treatment has been to use combinations of differently acting pharmacotherapies to improve weight loss with fewer adverse effects. The purpose of this study was to determine whether the combination of naltrexone (Nal), an opioid antagonist acting on the reward system, and exendin-4 (Ex-4), a glucagon-like peptide 1 agonist acting on satiety signaling, would produce larger reductions in food intake than either alone in rats. Because the anorectic potencies of both compounds have been associated with nausea and malaise, the influence of these drug combinations on the acquisition of a conditioned taste aversion (CTA) was also determined. METHODS: In Experiment 1, the acute anorectic effects of Nal (0.32 --3.2 mg kg À1 ; intraperitoneally (i.p.)) and Ex-4 (1 --10 mg kg À1 ; i.p.) were assessed alone or in combination. Combinational doses were further investigated by the repeated daily administration of 1 mg kg À1 Nal þ 3.2 mg kg À1 Ex-4 for 4 days. In Experiment 2, both compounds alone or in combination were used as unconditioned stimuli in a series of CTA tests. RESULTS: Nal and Ex-4, alone or in combination, suppressed food intake in a dose-dependent manner, and the interaction on food intake between Nal and Ex-4 was additive. In the CTA paradigm, Nal (1 mg kg
INTRODUCTION
Obesity and its comorbid health conditions, such as type 2 diabetes and cardiovascular diseases, have become worldwide health-care burdens and leading causes of death. 1 Reducing body weight (BW) is commonly considered as an important aim of obesity treatment because health-related complications of obesity can be ameliorated by weight management. The most clinically effective approach in terms of both the magnitude of weight loss and sustained effects is bariatric surgery. 2, 3 Although the efficacy of bariatric surgery is high, it is expensive and invasive and is targeted at only those with body mass index 440 or body mass index 435 with obesity-related comorbid conditions. 4 Effective pharmacological intervention, on the other hand, could potentially provide tremendous benefit for a greater portion of overweight individuals. However, there are few options currently approved by the Food and Drug Administration, Health Canada or the European Medicines Agency. In the United States, for example, the two medications available for obesity, phentermine and orlistat, are either not approved for long-term use (412 weeks) or are often not well tolerated. 5 Because food intake and BW are controlled by numerous overlapping physiological mechanisms, recent preclinical advances have been made in utilizing combinational drug therapies to treat obesity. 5 --7 Several combinational therapies for the treatment of obesity are presently in late-stage clinical trials or being further evaluated by the Food and Drug Administration or other regulatory agencies. 8 The use of combinational therapy offers the potential for synergistic interactions between compounds to produce a greater degree of weight loss than the sum of the individual effects of each compound. Given that smaller doses of each compound can be used to produce effective weight loss, compounds that interact in an additive or synergistic fashion also have the potential advantage of minimizing associated dose-dependent adverse effects.
In this study, we hypothesized that manipulating both the satiety and reward systems simultaneously would produce additive actions on food intake. We began to test this hypothesis with two clinically approved drugs to ensure individual drug safety. The glucagon-like peptide 1 (GLP-1) agonist exendin-4 (Ex-4) was chosen to enhance satiety function. Ex-4 is a naturally occurring peptide 9 that is resistant to dipeptidyl-peptidase IV degradation. 10 It is an incretin that increases the release of insulin to facilitate clearing blood glucose, and so a synthetic version of Ex-4 Byetta (Exenatide) has been approved for treating type 2 diabetes. Clinical reports have indicated that Ex-4 produces progressive weight loss in addition to its action on glucose homeostatsis. 11, 12 The opioid receptor antagonist naltrexone (Nal) was chosen to suppress the rewarding value of food. Nal is clinically approved for treating opioid and alcohol dependence. Reports from both human and animal studies have demonstrated that Nal can decrease food intake by decreasing food palatability. 13 --15 In this study, the anorectic potencies of the two drugs were measured alone or in combination. Additional experiments were performed to determine whether these combinations reduced food intake by aversive actions. Both of these drugs have been associated with aversive side effects. 11, 16, 17 Conditioned taste aversion (CTA) is a learned behavior that occurs when ingestion of a novel food is followed by visceral illness, which can be induced by drug treatment. Once a CTA is formed, the value of the food switches from preference to avoidance. 18 Thus, the CTA paradigm was used as a metric of avoidance to determine whether the Nal or Ex-4 or their combination devalued food. 18 
MATERIALS AND METHODS Animals
Two sets of male Sprague Dawley rats (Charles River, Wilmington, MA, USA), weighing 250 --275 g upon arrival, were used in this study. The first set n ¼ 8 were used for Experiment 1 to study the effects of Nal and Ex-4 and their combination on food intake. The second set n ¼ 30 were used for Experiment 2 to study the aversive effects of the same drug combinations. Rats were single housed with Prolab RHM 1000 (Brentwood, MO, USA) water available ad libitum except when stated otherwise. Food intake and BW were measured daily. All animal protocols were approved by the Institutional Animal Care and Use committee of the Johns Hopkins University.
Experiment 1: food intake Drugs. Naltrexone hydrochloride (Sigma-Aldrich, St Louis, MO, USA) and Ex-4 (Bachem, King of Prussia, PA, USA) were dissolved in 0.9% NaCl. The drug solutions were injected intraperitoneally in a volume of 1 ml kg À1 . The doses used for Nal were 0, 0.32, 1 and 3.2 mg kg À1 , and for Ex-4 were 0, 1, 3.2 and 10 mg kg À1 . For the combination treatments, the two drugs were dissolved together in saline for a single injection.
Short-term food intake. The effects of Nal or Ex-4 or dose combinations of the two drugs on short-term food intake were tested when the rats were mildly food restricted (4 h prior to the dark onset). On the test days, either saline or drug solutions were administered 10 --15 min before the onset of dark. Food was returned to the rats at the time of dark onset, and intake was measured at 1, 4 and 20 h afterwards. There were at least 2 days between each drug injection test. Once drug treatment began, saline treatment also occurred intermittently. Baseline intake was the mean of three initial saline injection tests and two additional tests during drug treatment.
Consecutive daily injection. When the rats were about 30 weeks old and had an average BW ¼ 638 ± 28.5 g, a dose combination of Nal (1 mg kg À1 )
and Ex-4 (3.2 mg kg
À1
) was administered once daily for 4 consecutive days to examine whether such treatment would produce sustained effects on food intake. The dose combination was chosen based on the results from short-term food intake tests. On average, this dose combination suppressed 75.8% food intake from saline injection at 1 h. Injections and intake measurements were conducted similarly as above.
Experiment 2: CTA learning During Experiment 1, it was observed that rats showed signs of malaise including lying on their belly and increased salivary secretion around the mouth after injections of the high-dose 10 mg kg À1 Ex-4. Thus, we examined whether the additive effects of food intake suppression were related to the aversive property of Nal and Ex-4, alone or in combination.
Group. Rats were divided into four groups that received intraperitoneal injections of either saline, Nal, Ex-4 or a mixture of Nal and Ex-4 (mix) as an unconditioned stimulus (US) for a CTA acquisition. CTA procedures. The CTA training and testing protocols were adapted from previous studies. 19, 20 Rats were overnight water deprived. The training included 15 min presentation of fluid and posttest 1 h rehydration with water. At baseline training, rats received water during the 15 min session. Once the water intake stabilized, rats received a 15 min presentation of a CS and 10 min after that an intraperitoneal injection of an US on the conditioning day. There were three conditioning trials and then a one 1-bottle (15 min CS presentation alone) test to evaluate the degree of aversion. Each CS presentation trial was separated by 2 days of water presentation. After acquiring a CTA to a CS, rats were returned to water and food ad lib for at least 1 week before the next CTA training with a new CS begun. Rats were re-grouped based on equal average BW for each CTA acquisition.
Statistical analyses
Food intake, BW and CS intake were analyzed using Statistica 7.1 (Tulsa, OK, USA). Cumulative food intakes were analyzed using mixed-model repeated-measures analysis of variance (ANOVA; Experiment 1, doses of drugs as within factors; Experiment 2, US treatment as predictor and conditioning and 1-bottle test trials as within factors). Post hoc comparisons were made with Fisher least significant difference tests. Food intake data of Experiment 1 were expressed as percentage of saline injection intake. Data from individual drug administration and dose combinations of Nal and Ex-4 were expressed in a quadratic surface plot, and a response surface methodology was used to determine whether the range of combinational doses resulted in an infra-additive, additive or supra-additive 21 --24 effects on food intake. On the basis of the previous response surface methodology, additivity was suggested by a P-value X0.05 and more than additivity (supra-additivity) P-value o0.05 for the interaction term. Data are expressed as means ± s.e.
RESULTS

Experiment 1: food intake testing
Individual drug administration. Acute food intake after individual doses of Nal was suppressed dose dependently at all three time points measured (Table 1 ). This is supported by one-way repeated measure ANOVA's revealing significant dose effects (1 h, F(3, 21) ¼ 11.5, Po0.001; 4 h, F(3, 21) ¼ 11.2, Po0.001; 20 h, F(3, 21) ¼ 12.6, Po0.0001). Similarly, administration of Ex-4 produced dosedependent suppressions of food intake (Table 1, 
Po0.003). There was no significant BW reduction in response to any one of these once a day injections (data not shown), likely due to the small level of intake suppression by 20 h. Overall, these results are consistent with previous reports that both Nal and Ex-4 reduce acute food intake.
Dose combinations of Nal and Ex-4. There were 9 dose combinations of Nal and Ex-4. From their respective saline baselines, these combination treatments resulted in dose-dependent reductions in food intake at all three time points measured (1 h, F(9, 63) ¼ 6.9, Po0.0001; 4 h, F(9, 63) ¼ 6.2, Po0.0001; 20 h, F(9, 63) ¼ 8.5, Po0.0001). Table 1 includes food intake results from each individual or combination dose administration at each time point measured. ANOVA comparing individual and combination (Nal, Ex-4 and Nal þ Ex-4) for each dose, Nal þ Ex-4 combinations had additive effects on food intake, that is, drug combinations reduced food intake more than did individual drugs alone. Response surface regression analyses also suggested additive effects at all three time points measured (Figure 1) . At 1 h, P-values for the Nal and Ex-4 terms were o0.001 and for the Nal þ Ex-4 interaction term was ¼ 0.087. At 4 h, P-values were o0.04 for the individual Nal and Ex-4 terms, and was 0.61 for the Nal þ Ex-4 interaction term. Finally at 20 h, P-values were 0.27 and o0.005, respectively, for the Nal and Ex-4 terms, and was 0.85 for the Nal þ Ex-4 interaction term. Here the P-value for Nal or Ex-4 indicates the significant dose-dependent food intake suppression for the two drugs alone. These results are consistent with the ANOVA results that revealed dose-dependent effects on food intake suppression. On the basis of what has been defined by others using combinational interactions and response surface methodology, 21, 22, 25 the P-values for the drug combination indicate additive or supra-additive effects on food intake. Because the P-values for drug combinations at each time point were 40.05, the Nal and Ex-4 combinations produced additive suppressive effects on food intake. Figure 1 . Quadratic surface plots for cumulative food intake at 1, 4 and 20 h after intraperitoneal administrations of doses of Nal or Ex-4 alone and the two drugs combined. Data are presented as percentage of the corresponding hourly saline injection intake. The bottom tips of all three surface plots do not extend to the front junction of the Ex-4 and Nal axis, suggesting additive effects on food intake suppression after treatments of Nal þ Ex-4 at all time points measured. These additive effects are confirmed by response surface regression (see Experiment 1 in Results section). ) þ Ex-4 (3.2 mg kg À1 ) on food intake. Combination of Nal þ Ex-4 produced sustained reduction in food intake at 1 and 4 h. The reduction in food intake at 20 h gradually declined. By the 4th day, food intake was not significantly reduced at 20 h. (*, versus saline, Po0.05). intake tests, such dose combinations produced a large suppression of food intake at 1 and 4 h (50 --90% reduction from their respective saline injection intake, Po0.003). The intake suppression occurred after each daily injection. The reduction in intake from saline injection was smaller at 20 h (15 --25%, Po0.003 from day 1 to 3). However, the suppression effect on food intake at 20 h was not significant on day 4. Overall, the consecutive injections of 1 mg kg À1 Nal þ 3.2 mg kg À1 Ex-4 combination did not result in any reduction of BW (starting average weight ¼ 638.5 ± 28.5 g versus ending weight ¼ 641.2±30.5 g).
Experiment 2: CTA testing Nal (1 mg kg
À1
) and Ex-4 (3.2 mg kg
). The results of 1 mg kg À1 Nal and 3.2 mg kg À1 Ex-4 alone or combined for conditioned aversion to 0.3 M sucrose are shown in Figure 3 . Repeated measure ANOVA revealed significant effects of group (F(3, 26) ¼ 16.1, Po0.0001), trial (F(3, 78) ¼ 7.6, Po0.0002) and group Â trial interaction (F(9, 78) ¼ 11.0, Po0.0001). After three conditioning sessions, rats that received either Ex-4 or the combination of 1 mg kg À1 Nal þ 3.2 mg kg À1 Ex-4 learned to avoid the sucrose CS in the 1-bottle test trial. The aversive effects of Ex-4 and the Ex-4 þ Nal combination were also demonstrated by rats lying on their belly after the injection. Nal at 1 mg kg À1 had no aversive effect. Rats that received this dose maintained large volumes of sucrose intake as did the Saline group. Thus, it appeared that the aversion effect at the dose combination of 1 mg kg À1 Nal þ 3.2 mg kg À1 Ex-4 was mainly from Ex-4.
Nal (3.2 mg kg
À1
) and Ex-4 (1 mg kg
). In order to test whether using a combination of a higher dose Nal and a lower dose Ex-4 would produce less aversive effects, a dose combination of 3.2 mg kg À1 Nal þ 1 mg kg À1 Ex-4 was used for conditioned aversion to 0.15 M NaCl. This combination produced an additive effect on food intake in Experiment 1. Figure 4 summarizes the results of the CTA acquisition. After three conditioning trials, rats that received this combination treatment greatly reduced their intake of NaCl. Compared to trial 1 NaCl intake, rats that received Ex-4 also had a significant decrease in NaCl intake during the 1-bottle test (Po0.002). Although the dose combination group drank less NaCl than did the Ex-4 group at 1-bottle test, post hoc tests revealed no significant difference between them (P ¼ 0.12). Rats that received Nal during conditioning drank significantly less NaCl during 1-bottle test than those received Saline group rats (Po0.03). However, there was no significant reduction in NaCl intake from initial trial 1 in Nal-treated rats (P ¼ 0.21). Overall, repeated measured ANOVA confirmed significant effects of group (F(3, 26) ¼ 3.2, Po0.04), trial (F(3, 78) ¼ 5.3, Po0.003) and group Â trial interaction (F(9, 78) ¼ 6.2, Po0.0001). Because rats with this combination treatment reduced NaCl intake significantly sooner than with those that received Ex-4 alone, results in NaCl CTA acquisition suggested that additive effects of Nal and Ex-4 combination may also occur on conditioned food aversion.
Nal (1 mg kg
À1 ) and Ex-4 (1 mg kg À1 ). To further assess the aversive effects of combinations of Nal and Ex-4, smaller doses of Nal (1 mg kg
À1
) and Ex-4 (1 mg kg À1 ) that produced either no or mild CTA when given alone were used. In these experiments, the CS was 0.006 M citric acid. The results of citric acid CTA after 1 mg kg À1 Nal and 1 mg kg À1 Ex-4 are summarized in Figure 5 . Repeated measured ANOVA reveled that both Ex-4 and the ), and mix (Nal þ Ex-4) injections both significantly reduced their intake of NaCl over trials. Rats in the mix group also significantly reduced NaCl intake more than the Ex-4 rats (*, mix versus the other three groups, Po0.05; #, mix versus saline or Nal, Po0.05). ) did not learn to avoid citric acid. Rats that received Ex-4 (1 mg kg À1 ), and mix (Nal þ Ex-4) injections acquired a CTA and avoided citric acid after three pairing trials. Rats in the mix group also significantly reduced citric acid intake sooner than the Ex-4 rats (*, mix versus the other three groups, Po0.05; #, Ex-4 or mix versus saline or Nal, Po0.05).
Trials
combination treatment produced conditioned aversion to citric acid (group, F(3, 21) ¼ 12.7, Po0.0001; trial, F(3, 63) ¼ 5.5, Po0.003; group Â trial interaction, F(9, 63) ¼ 10.6, Po0.0001). Rats treated with this combination greatly avoided citric acid after 1 conditioning trial, and thus acquired aversion sooner than rats treated with Ex-4. Consistent with the sucrose CTA results, Nal at 1 mg kg À1 did not result in avoidance to citric acid after three conditioning training. Overall, these results also showed that combinations of Nal and Ex-4 can produce additive effects on not only food intake but also on food aversion learning.
DISCUSSION
The initial hypothesis in this study was that co-administration of compounds acting on different mechanisms involved in controlling food intake would produce larger suppression on food intake than either one of them alone. Furthermore, it was hypothesized that when additive effects of the combination occurred, requiring a smaller dose of individual drugs to decrease food intake, the most common adverse effect of the two drugs, nausea, would be ameliorated. Thus, the acute effects of individual and combined peripheral treatment of Nal and Ex-4 on food intake and CTA were examined. The results revealed that Nal and Ex-4 combination produced greater suppressions of short-term food intake than either of them individually. Because the two drugs deviated in their constant relative potency on food intake, there is an inherent difficulty in examining their pharmacological relationship. While response surface methodology can be used where the simple isobolographic method cannot, our assessment of potential synergy is somewhat limited because of the lack of constant relative potency. 26 However, our conclusion of additivity is conservative and consistent with the results of the ANOVA. Overall, the anorectic effect of the Nal þ Ex-4 combination could be associated with an induced avoidance as there was larger and more rapid suppression of the CS intake in CTA with Nal þ Ex-4 than when each compound was administered alone.
Combinational therapies have been applied to treat multiple chronic diseases such as hypertension and diabetes, and many drug combinations to treat obesity are under investigation. 5 One of them is Contrave, which combines Nal and bupropion. In this case, Nal the opioid antagonist was chosen based on its ability to increase the activity of pro-opiomelanocortin neurons in the arcuate nucleus of the hypothalamus to produce anorectic effects. 7 In our experiments, we chose Nal based on its effects on the rewarding component of food. Many studies have demonstrated that the opioid system in the striatum contributes to the palatability of foods.
14,27 --29 Although Nal alone is associated with minimal weight loss, 30, 31 combining it with bupropion has been reported to result in supra-additive effects on food intake and BW reduction. 7 In our present research, we combined Nal with the GLP-1 receptor agonist Ex-4. Initially, Ex-4 was chosen for its satiety action. However, recent work has also suggested direct effects of GLP-1 on the reward system. 32, 33 Thus the combination would affect multiple systems underlying feeding control. The combination produced additive effects on short-term intake suppression. Moreover, consecutive once a day Nal þ Ex-4 treatment for 4 days revealed a persistent effect of short-term intake reduction, but no effects on BW. It also appeared that some tolerance occurred at this dose combination over 4-day consecutive treatment. Although not statistically significant, a clear trend of reduced intake suppression was found for 20 h accumulative food intake ( Figure 2) .
While the GLP-1 agonist Ex-4 is an Food and Drug Administration approved anti-diabetic drug, its use has produced significant weight loss in human. 34 Besides the gut, GLP-1 is expressed in neurons in the nucleus of the solitary tract (NST) and the GLP-1 receptors are expressed there and widely throughout other brain regions. 35 --37 These NST GLP-1 containing neurons largely project to the paraventricular nucleus of the hypothalamus, and a significant amount project to other forebrain regions including the ventral tegmental area and the nucleus accumbens. 32, 33, 38 Central GLP-1 pathway activation results not only in food intake reduction but also in food avoidance. For example, injections of GLP-1 in the amygdala can produce malaise as measured by a CTA test, 39, 40 while intracerebral ventricular GLP-1 antagonists block CTA induced by LiCl. 41 Furthermore, peripheral LiCl injection activates GLP-1 containing neurons in the NST and those neurons project to the paraventricular nucleus of the hypothalamus. 42 These data indicate that central GLP-1 systems are involved in CTA learning. In this study, Ex-4 and Nal þ Ex-4 combination were administered peripherally. Previous studies have suggested that the sites of action of peripherally administered GLP-1 agonists can be both peripheral and central. 43 --45 Furthermore, it has been demonstrated that Ex-4 can penetrate the brain rapidly. 46 Accordingly, our food intake and CTA results with Ex-4 could be induced by both peripheral and central activation of the GLP-1 receptors. 47 Although it is unclear whether the food intake and avoidance effects here involve the same populations of GLP-1 neurons or neurons that express GLP-1 receptors, recent studies showing food intake affected by GLP-1 neurons and receptors in the ventral tegmental area and nucleus accumbens 32, 33 suggest that GLP-1 analogs may also be viewed as agents that acts on not only satiety but also reward mechanisms. Given that the opioid receptors are also expressed in similar brain regions, the interactions between Nal and Ex-4 could potentially occur at multiple central or peripheral sites to control ingestion.
The ability of Ex-4 to induce malaise or visceral illness varies across different animal models. In the rat, there have been mixed results with two commonly used methods to examine the aversive properties of anorexigenic drugs, pica and CTA. 23 Pica refers to ingestion of non-nutritive substances such as clay or Kaolin. Rodents show Kaolin hyperphagia in response to toxic treatments such as LiCl injection. 48, 49 When using pica behavior to measure the aversive property of the drug in Sprague Dawley rats, none of the tested Ex-4 doses (0.1 --10 mg kg À1 ) induced kaolin intake. 50 In Wistar and Sprague Dawley rats, peripheral Ex-4 can induce a CTA or decrease locomotor activity at a dose much higher than the threshold dose for reducing food intake. 50, 51 However, Hayes and colleagues 52 recently demonstrated that peripheral Ex-4 induces both CTA (0.25 --3.0 mg kg À1 ) and pica (3 mg kg À1 b.i.d.). Our data are similar to those of Hayes and colleagues. The reasons for the difference among the various experiments are not clear. However, the paradigm we used with three pairings is considered to be especially sensitive.
The aversive effects of Ex-4 have not been as widely reported in experiments with mice and primates. One study demonstrated that the effective peripheral dose to reduce food intake is 50 times lower than the dose to induce CTA in mice. 53 In nonhuman primates, a dose-dependent reduction in meal size in response to Ex-4 has been reported. 21, 54 At doses (0.1 --3.0 mg kg À1 ) tested, meal numbers were not changed, and the monkeys did not show any obvious signs of malaise. 54 These data translate better to the responses in humans taking Ex-4 for diabetes treatment. Although nausea is the most commonly reported adverse effect of Exenatide (B38%), the symptom declines or stops over time. 11, 55 It has also been suggested that the occurrence of nausea can be greatly reduced if the GLP-1 agonist is taken by gradually increasing the dose. Overall, it is suggested that malaises related to Ex-4 can be improved or excluded overtime in humans.
The results of our study, nevertheless, are in line with the rat data revealing that Ex-4 reduces food intake and produces robust conditioned food avoidance. In Experiment 2, group assignment was reorganized for another CTA with a different CS after the initial conditioned avoidance acquisition. With this method, some rats ended up receiving saline or Nal as the US treatment for the second or third CTA acquisition and some rats repeatedly received the US that contained either Ex-4 alone or combined with Nal. At first glance, this design may complicate the interpretation of the results because the intake of the three different CSs at the first trial differed. However, the fact that there were no group differences in the initial intakes of all three CSs supports the following implications. First, across the doses tested, the aversive effect of Ex-4 was greater than that of Nal. When Nal alone was the US, only the higher dose 3.2 mg kg À1 reduced CS intake (B22%), but this reduction was not statistically significant. At the lower dose 1 mg kg À1 , Nal did not reduce intake of either NaCl or citric acid CS during the test trial. However, significant CTA was formed at every doses of Ex-4 tested. At the lowest Ex-4 dose tested (1 mg kg À1 ), rats developed a 50% CS intake reduction by the 1-bottle test trial with either NaCl or citric acid as the CS. Second, in contrast to human data, previous experience with Ex-4 did not ameliorate its aversive effects. That is, no matter whether the rats were naive or experienced with a US that included Ex-4, they developed avoidance to the CS, and the rate of CTA acquisition was not decreased or increased with previous Ex-4 experience. It is possible that acclimating rats to Ex-4 treatments for an extended period of time would ameliorate CTA in the future. However, there was no evidence for this in this study. Finally, in the group that received the combination treatments, the rats acquired avoidance sooner and stronger when the low-dose Ex-4 (1 mg kg
À1
) was combined with either high-or low-dose Nal. Thus, these data indicate that the aversive effect of the combined treatment (Nal þ Ex-4) was primarily from Ex-4, and the combination can produce additive effects on conditioned avoidance.
Data presented here support that the Nal and Ex-4 combinations have additive effects on food intake suppression. This is consistent with the idea of using compounds that act on both the satiety and hedonic aspects of food intake to develop combinational therapy for obesity. However, inconsistent with the assumption that compounds that interact in an additive or synergistic fashion may have the advantage of minimizing dosedependent adverse effects associated with individual compound, the data indicate that these drug combinations actually produce stronger malaise side effects in rat. Such data enhance the importance of examining not only the desired but also the adverse effects of combinational therapy at early stages of drug development.
